U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06822478) titled 'Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis (phase III)' on Feb. 06.
Brief Summary: Cutaneous leishmaniasis (CL) is a parasitic disease caused by more than 20 different species of the protozoan parasite Leishmania. CL usually begins with a papule at the site of the sandfly bite, which enlarges to form a nodule that progresses to an ulceration, or a scaly or warty plaque, over a period of 1 to 3 months.
The exact incidence of CL is not known. An estimated 1.2 million cases/year in approximately 100 countries worldwide suffer from different forms of CL. More than 90% of CL cases occur in the Americas and Eastern Medi...